In recent years, immunotherapy for HCC has seen advancements in the use of immune checkpoint inhibitors such as PD-1, PD-L1, and CTLA-4 antibodies, offering new hope for treatment 38. Here, CTLA4 is linked to hepatocellular carcinoma.